# Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

> **NCT01329809** · PHASE2 · TERMINATED · sponsor: **Jennerex Biotherapeutics** · enrollment: 2 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

## Key facts

- **NCT ID:** NCT01329809
- **Lead sponsor:** Jennerex Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2012-01
- **Final completion:** 2013-03
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2013-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01329809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01329809, "Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01329809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*